Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

Marc Girard, Marie Paule Kieny, Abraham Pinter, Francoise Barre-Sinoussi, Peter Nara, Hanno Kolbe, Kenro Kusumi, Agnes Chaput, Todd Reinhart, Elizabeth Muchmore, Jorge Ronco, Michel Kaczorek, Elisabeth Gomard, Jean Claude Gluckman, Patricia N. Fultz

Research output: Contribution to journalArticle

292 Citations (Scopus)

Abstract

Sustained high titers of neutralizing antibodies were elicited in three chimpanzees after sequential injections of different human immunodeficiency virus 1 (HIV-1) antigen preparations derived from the HIV-1 BRU strain that included whole inactivated virus or purified recombinant proteins and then synthetic peptides identical to the major HIV-1 neutralizing epitope V3. The animals were challenged i.v. with 40 chimpanzee infectious doses (equivalent to 100 tissue culture 50% infectious doses) of a stock of HIV-1 IIIB isolate. After 6 mo of follow-up, all three animals appeared uninfected by serologic and virologic criteria, including polymerase chain reaction analysis and failure to isolate virus from peripheral blood lymphocytes, bone marrow, and lymph node tissue. Of two chimpanzees monitored for 1 yr, virus was isolated initially from one animal at 32 weeks, but the second chimpanzee was virus negative by all assays through 12 mo; the third animal has remained virus negative through 9 mo of follow-up. These results indicate that it is possible to elicit protection against, or significantly delay infection of, HIV-1 by immunization, thus laying the foundation for development of an HIV-1 vaccine.

Original languageEnglish (US)
Pages (from-to)542-546
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume88
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

Pan troglodytes
HIV-1
Immunization
HIV
Viruses
Neutralizing Antibodies
Recombinant Proteins
Epitopes
Vaccines
Lymph Nodes
Bone Marrow
Lymphocytes
Antigens
Polymerase Chain Reaction
Peptides
Injections
Infection

Keywords

  • AIDS
  • Neutralizing antibodies
  • Vaccine

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Girard, M., Kieny, M. P., Pinter, A., Barre-Sinoussi, F., Nara, P., Kolbe, H., ... Fultz, P. N. (1991). Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences of the United States of America, 88(2), 542-546.

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. / Girard, Marc; Kieny, Marie Paule; Pinter, Abraham; Barre-Sinoussi, Francoise; Nara, Peter; Kolbe, Hanno; Kusumi, Kenro; Chaput, Agnes; Reinhart, Todd; Muchmore, Elizabeth; Ronco, Jorge; Kaczorek, Michel; Gomard, Elisabeth; Gluckman, Jean Claude; Fultz, Patricia N.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, No. 2, 1991, p. 542-546.

Research output: Contribution to journalArticle

Girard, M, Kieny, MP, Pinter, A, Barre-Sinoussi, F, Nara, P, Kolbe, H, Kusumi, K, Chaput, A, Reinhart, T, Muchmore, E, Ronco, J, Kaczorek, M, Gomard, E, Gluckman, JC & Fultz, PN 1991, 'Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus', Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 2, pp. 542-546.
Girard, Marc ; Kieny, Marie Paule ; Pinter, Abraham ; Barre-Sinoussi, Francoise ; Nara, Peter ; Kolbe, Hanno ; Kusumi, Kenro ; Chaput, Agnes ; Reinhart, Todd ; Muchmore, Elizabeth ; Ronco, Jorge ; Kaczorek, Michel ; Gomard, Elisabeth ; Gluckman, Jean Claude ; Fultz, Patricia N. / Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. In: Proceedings of the National Academy of Sciences of the United States of America. 1991 ; Vol. 88, No. 2. pp. 542-546.
@article{701b4c6a68344d5293c415adff6b4b8a,
title = "Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus",
abstract = "Sustained high titers of neutralizing antibodies were elicited in three chimpanzees after sequential injections of different human immunodeficiency virus 1 (HIV-1) antigen preparations derived from the HIV-1 BRU strain that included whole inactivated virus or purified recombinant proteins and then synthetic peptides identical to the major HIV-1 neutralizing epitope V3. The animals were challenged i.v. with 40 chimpanzee infectious doses (equivalent to 100 tissue culture 50{\%} infectious doses) of a stock of HIV-1 IIIB isolate. After 6 mo of follow-up, all three animals appeared uninfected by serologic and virologic criteria, including polymerase chain reaction analysis and failure to isolate virus from peripheral blood lymphocytes, bone marrow, and lymph node tissue. Of two chimpanzees monitored for 1 yr, virus was isolated initially from one animal at 32 weeks, but the second chimpanzee was virus negative by all assays through 12 mo; the third animal has remained virus negative through 9 mo of follow-up. These results indicate that it is possible to elicit protection against, or significantly delay infection of, HIV-1 by immunization, thus laying the foundation for development of an HIV-1 vaccine.",
keywords = "AIDS, Neutralizing antibodies, Vaccine",
author = "Marc Girard and Kieny, {Marie Paule} and Abraham Pinter and Francoise Barre-Sinoussi and Peter Nara and Hanno Kolbe and Kenro Kusumi and Agnes Chaput and Todd Reinhart and Elizabeth Muchmore and Jorge Ronco and Michel Kaczorek and Elisabeth Gomard and Gluckman, {Jean Claude} and Fultz, {Patricia N.}",
year = "1991",
language = "English (US)",
volume = "88",
pages = "542--546",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "2",

}

TY - JOUR

T1 - Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

AU - Girard, Marc

AU - Kieny, Marie Paule

AU - Pinter, Abraham

AU - Barre-Sinoussi, Francoise

AU - Nara, Peter

AU - Kolbe, Hanno

AU - Kusumi, Kenro

AU - Chaput, Agnes

AU - Reinhart, Todd

AU - Muchmore, Elizabeth

AU - Ronco, Jorge

AU - Kaczorek, Michel

AU - Gomard, Elisabeth

AU - Gluckman, Jean Claude

AU - Fultz, Patricia N.

PY - 1991

Y1 - 1991

N2 - Sustained high titers of neutralizing antibodies were elicited in three chimpanzees after sequential injections of different human immunodeficiency virus 1 (HIV-1) antigen preparations derived from the HIV-1 BRU strain that included whole inactivated virus or purified recombinant proteins and then synthetic peptides identical to the major HIV-1 neutralizing epitope V3. The animals were challenged i.v. with 40 chimpanzee infectious doses (equivalent to 100 tissue culture 50% infectious doses) of a stock of HIV-1 IIIB isolate. After 6 mo of follow-up, all three animals appeared uninfected by serologic and virologic criteria, including polymerase chain reaction analysis and failure to isolate virus from peripheral blood lymphocytes, bone marrow, and lymph node tissue. Of two chimpanzees monitored for 1 yr, virus was isolated initially from one animal at 32 weeks, but the second chimpanzee was virus negative by all assays through 12 mo; the third animal has remained virus negative through 9 mo of follow-up. These results indicate that it is possible to elicit protection against, or significantly delay infection of, HIV-1 by immunization, thus laying the foundation for development of an HIV-1 vaccine.

AB - Sustained high titers of neutralizing antibodies were elicited in three chimpanzees after sequential injections of different human immunodeficiency virus 1 (HIV-1) antigen preparations derived from the HIV-1 BRU strain that included whole inactivated virus or purified recombinant proteins and then synthetic peptides identical to the major HIV-1 neutralizing epitope V3. The animals were challenged i.v. with 40 chimpanzee infectious doses (equivalent to 100 tissue culture 50% infectious doses) of a stock of HIV-1 IIIB isolate. After 6 mo of follow-up, all three animals appeared uninfected by serologic and virologic criteria, including polymerase chain reaction analysis and failure to isolate virus from peripheral blood lymphocytes, bone marrow, and lymph node tissue. Of two chimpanzees monitored for 1 yr, virus was isolated initially from one animal at 32 weeks, but the second chimpanzee was virus negative by all assays through 12 mo; the third animal has remained virus negative through 9 mo of follow-up. These results indicate that it is possible to elicit protection against, or significantly delay infection of, HIV-1 by immunization, thus laying the foundation for development of an HIV-1 vaccine.

KW - AIDS

KW - Neutralizing antibodies

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0025965050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025965050&partnerID=8YFLogxK

M3 - Article

C2 - 1988952

AN - SCOPUS:0025965050

VL - 88

SP - 542

EP - 546

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 2

ER -